Patents by Inventor Brian R. Kusche

Brian R. Kusche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7998962
    Abstract: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radiolabelled 2?-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2?-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: August 16, 2011
    Assignee: The University of Montana
    Inventors: John M. Gerdes, David B. Bolstad, Brian R. Kusche
  • Publication number: 20110009419
    Abstract: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radiolabelled 2?-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2?-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain.
    Type: Application
    Filed: September 22, 2010
    Publication date: January 13, 2011
    Inventors: John M. Gerdes, David B. Bolstad, Brian R. Kusche
  • Patent number: 7812162
    Abstract: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radio-labelled 2?-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2?-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: October 12, 2010
    Assignee: The University of Montana
    Inventors: John M. Gerdes, David B. Bolstad, Brian R. Kusche